MiMedx Group (MDXG) Expected to Announce Quarterly Earnings on Wednesday

MiMedx Group (NASDAQ:MDXG - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results after the market closes on Wednesday, April 30th. Analysts expect MiMedx Group to post earnings of $0.06 per share and revenue of $86.32 million for the quarter.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The business had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. On average, analysts expect MiMedx Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiMedx Group Trading Up 2.0 %

Shares of NASDAQ MDXG opened at $6.68 on Wednesday. The stock has a market capitalization of $984.40 million, a P/E ratio of 12.15 and a beta of 1.74. The stock's 50 day moving average price is $7.62 and its two-hundred day moving average price is $8.03. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. MiMedx Group has a 52-week low of $5.47 and a 52-week high of $10.14.

Insider Buying and Selling

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares in the company, valued at approximately $3,473,004.42. This represents a 11.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares in the company, valued at approximately $2,452,496.04. This represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 144,018 shares of company stock worth $1,130,312 in the last three months. 1.30% of the stock is owned by insiders.

Analyst Ratings Changes

MDXG has been the topic of several research analyst reports. StockNews.com cut MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, April 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $13.00 price target on shares of MiMedx Group in a report on Thursday, February 27th.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.